About us
Ambusol is a clinical-stage cancer therapeutics company pioneering a patented approach to treat post-surgical Stage IV glioblastoma (GBM). Our mission is to eradicate residual cancer cells in the surgical margins and significantly improve patient outcome
The development of our artificial amino acid molecule is grounded in over 50 years of pioneering research conducted by Dr. Gunnar Ronquist at the University Hospital in Uppsala, Uppsala University, and the University of Michigan in Ann Arbor.
This extensive body of work spans key areas including cellular transport systems, ion pump mechanisms, intercellular communication via extracellular vesicles (EVs), the role of EVs in shaping the tumor microenvironment.
The artificial amino acid therapy we are advancing is a direct result of this scientific foundation building on decades of insight into how malignant cells interact with and exploit their microenvironment to drive tumor growth and evade treatment.